Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
The Prognostic Role of Circulating Dna Markers in Patients With Lung Malignancies: A Systematic Review and Meta-Analysis Publisher



Sz Kazemiharikandei Sayedeh ZAHRA ; Mr Salmani Jelodar Mohammad REZA ; Gh Roshandel Gholamreza H ; Sm Tavangar Seyed MOHAMMAD
Authors

Source: Biomarkers in Medicine Published:2025


Abstract

Aims: We aimed to explore the prognostic role of circulating DNA-related markers to improve clinical decision-making in patients with lung malignancies. Methods: A systematic search was performed on PubMed, Scopus, and Web of Science. Results: About 133 articles were included, comprising 5750 EGFR-positive, 1583 ALK-positive, and 9657 patients without specified genetic groups. Circulating tumor DNA (ctDNA) response was a significant prognostic marker associated with improved overall survival (OS) (HR = 0.36 [0.27, 0.47], I2 = 0%) and progression-free survival (PFS) (HR = 0.31 [0.18, 0.55], I2 = 67.33%) in advanced non-small cell lung cancer (NSCLC). Meta-analysis of tumor mutational burden (TMB) in the same group demonstrated trends toward poorer survival outcomes for higher TMB -pooled HR of 1.63 (95%-CI: 0.92, 2.88, I2 = 71.23%) for OS and 1.09 (95%-CI: 0.63, 1.89, I2 = 86.66%) for PFS. Finally, meta-analysis in advanced EGFR-positive NSCLC implicated significant prognostic effect of EGFR response positivity on OS and PFS -pooled HR of 0.39 and 0.27, respectively. Conclusion: Circulating DNA markers entailed valuable information in patient prognostication and depicting treatment efficacies in lung cancer. Further studies are needed to decipher more robust criteria for the presently accepted markers–namely ctDNA and EGFR response measures. Additionally, there are several markers–i.e. TMB–that have more exploratory clinical benefits. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Liquid Biopsy in Pediatric Urogenital Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
2. The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to Any Systematic Therapy: A Systematic Review, Current Stem Cell Research and Therapy (2019)
3. Circulating Tumor Dnas and Non-Coding Rnas As Potential Biomarkers for Hepatocellular Carcinoma Diagnosis, Prognosis and Response to Therapy, Hepatoma Research (2019)
Experts (# of related papers)
View all Related Experts
Naghmeh Bahrami (7)
Reza Malekzadeh (2)
Other Related Docs
4. Prognostic and Therapeutic Significance of Circulating Tumor Cells in Patients With Lung Cancer, Cellular Oncology (2020)
5. Advances in Blood Dna Methylation-Based Assay for Colorectal Cancer Early Detection: A Systematic Updated Review, Gastroenterology and Hepatology from Bed to Bench (2024)
6. Cell Free Tumoral Dna Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients With Non-Small Cell Lung Cancer, Asian Pacific Journal of Cancer Prevention (2019)
7. Overview of Liquid Biopsy, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
8. Tp53 Targeted Deep Sequencing of Cell-Free Dna in Esophageal Squamous Cell Carcinoma Using Low-Quality Serum: Concordance With Tumor Mutation, International Journal of Molecular Sciences (2021)
9. Expression of Two Basic Mrna Biomarkers in Peripheral Blood of Patients With Non-Small Cell Lung Cancer Detected by Real-Time Rt-Pcr, Individually and Simultaneously, Iranian Biomedical Journal (2015)
10. Investigating Gene Expression Level of Muc1 and Cea in Pleural Fluid of Nsclc Lung Cancer Patients With Real-Time Rt-Pcr Method, Minerva Pneumologica (2017)
11. Analysis of the Relationship Between Egfr Mutations and Pd-L1, Alk, and Ros1 Alterations in Patients With Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran; [Analysis of the Relationship Between Egfr Mutations and Pd-L1, Alk, and Ros1 Alterations in Patients With Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran], Turk patoloji dergisi (2025)
12. Diagnostic Value of Lunx Mrna and Cea Mrna Expression in Pleural Fluid of Patients With Non-Small Cell Lung Cancer, Minerva Pneumologica (2017)
13. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
14. Predictive Molecular Blood Biomarkers in Non-Small Cell Lung Cancer, Journal of Cellular and Molecular Anesthesia (2022)
15. Expression of Mir-155 and Cea and Vegf Proteins As Diagnostic Markers in Early Stages of Non-Small Cell Lung Cancer in Peripheral Blood, Tanaffos (2024)
16. Current Biological Implications and Clinical Relevance of Metastatic Circulating Tumor Cells, Clinical and Experimental Medicine (2025)
17. Ectopic Expression of Mirna-21 and Mirna-205 in Non-Small Cell Lung Cancer, International Journal of Cancer Management (2019)
18. Beyond Biomarkers: Exploring the Diverse Potential of a Novel Phosphoprotein in Lung Cancer Management, Journal of Cellular and Molecular Medicine (2024)
19. Increasing or Decreasing the Expression of Mir-199, Mir-210 and Mir-143 and the Effect on Cell Growth, Apoptosis and Angiogenesis Through the Expression of Target Genes in Non-Small Cell Lung Cancer, Minerva Respiratory Medicine (2022)
20. Design and Methodological Considerations for Biomarker Discovery and Validation in the Integrative Analysis of Lung Cancer Etiology and Risk (Integral) Program, Annals of Epidemiology (2023)